PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

23rd Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 8th October 2025 (Educational supporters)

Update on novel PCSK9-targeted therapies: Lerodalcibep

Update on novel PCSK9-targeted therapies: Lerodalcibep

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Frederick J. Raal   Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation…

read more »
Posted on 4 November 2025 | Posted by Frederick J. Raal | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
Update on novel PCSK9-targeted therapies: AZD0780

Update on novel PCSK9-targeted therapies: AZD0780

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Marc Bonaca   Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or…

read more »
Posted on 19 November 2025 | Posted by Marc Bonaca | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
Will the advent of oral PCSK9 inhibitors change the clinical scenery in ASCVD? Setting the scene

Will the advent of oral PCSK9 inhibitors change the clinical scenery in ASCVD? Setting the scene

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Professor François Mach   Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or…

read more »
Posted on 4 November 2025 | Posted by Francois Mach | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
Combination therapy: Real world experience in Germany

Combination therapy: Real world experience in Germany

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Klaus Parhofer   Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or…

read more »
Posted on 4 November 2025 | Posted by Klaus Parhofer | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
ORION-13 Inclisiran therapy in adolescent homozygous FH

ORION-13 Inclisiran therapy in adolescent homozygous FH

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Albert Wiegman   Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation…

read more »
Posted on 4 November 2025 | Posted by Albert Wiegman | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
PCSK9 and PCSK7: A tale of two non-identical twins in the regulation of cardiovascular disease and immune function

PCSK9 and PCSK7: A tale of two non-identical twins in the regulation of cardiovascular disease and immune function

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Nabil G. Seidah   Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation…

read more »
Posted on 22 October 2025 | Posted by Nabil G. Seidah | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
PCSK9-targeted therapy and atherosclerotic plaque remodelling

PCSK9-targeted therapy and atherosclerotic plaque remodelling

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Steve Nicholls Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation…

read more »
Posted on 22 October 2025 | Posted by Steve Nicholls | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
What have PCSK9 mAb trials taught us about lipoprotein(a)?

What have PCSK9 mAb trials taught us about lipoprotein(a)?

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Gregory G. Schwartz Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or…

read more »
Posted on 22 October 2025 | Posted by Gregory G. Schwartz | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.

LIB Therapeutics

Novartis

Sanofi

© Copyright 2026 PCSK9 Forum. All rights reserved